4D Molecular Therapeutics Shares Jump After Early Data From Wet Age-Related Macular Degeneration Trial

  • 4D Molecular Therapeutics Inc FDMT announced interim clinical data from cohort 1 of the Phase 1/2 trial of intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD). 
  • 4D-150 was safe and well tolerated, with no serious adverse events or dose-limiting toxicities reported.
  • No clinically significant intraocular inflammation, endophthalmitis, retinal vasculitis, retinal artery occlusion, choroidal effusions, and hypotony were reported to date.
  • Also see: 4D Molecular Shares Fall After Filing For Fabry Disease Trial Amendment.
  • Cohort 1 patients (n=5) received a single intravitreal injection of 4D-150 (3E10 vg/eye); these patients were high-need patients who, in the 12 months preceding trial enrollment, had a mean annualized anti-VEGF injection rate of ~11.
  • Following intravitreal 4D-150, the annualized anti-VEGF injection rate was reduced by 96.7%.
  • 80% of patients have remained anti-VEGF injection-free, with a follow-up of ~40, 36, 32, or 16 weeks.
  • The company expects to initiate enrollment in the randomized Phase 2 stage of the trial in Q1 2023. 
  • Additional clinical data from all three Dose Exploration cohorts on this trial is expected in Q2 2023.
  • Price Action: FDMT shares are up 8.11% at $13.52 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!